CPhI Worldwide Announces International Advisory Board

21.01.2015 -

CPhI Worldwide has announced the launch of a new advisory board, consisting of the following industry experts who provide a wide expertise portfolio:

  1. Alan Sheppard, Principal, Global Generics, Thought Leadership, IMS Health
    Specialist field: Generics, Biosimilars, Emerging Markets
  2. Brian Carlin, Director, Open Innovation, FMC
    Specialist field: Excipients, Formulation
  3. Dilip G Shah, CEO at Vision Consulting
    Specialist field: Indian and worldwide regulatory
  4. Frederic Kahn, Vice President Key Account Management, Gerresheimer
    Specialist field: Packaging
  5. Giles Breault, Founder, The Beyond Group
    Specialist field: Partnerships
  6. Jan Ramakers, Owner, Fine Chemical Consulting Group
    Specialist field: Fine Chemicals, Supply Chain
  7. Kurt Nielsen, Chief Technology Officer and Senior Vice President, R&D, Catalent
    Specialist field: Drug Delivery, Contract Manufacturing
  8. Lukas Utiger, President, DPx Fine Chemicals
    Specialist field: Fine Chemicals, Supply Chain
  9. Marlene Llopiz, Director for International Strategies and Regulatory Affairs, Probiomed
    Specialist field: LATAM market, Regulatory, Clinical Trials
  10. Martin Folger, Head of Pharmaceutical Development, Boehringer Ingelheim Vetmedica
    Specialist field: Animal Health, Drug Delivery
  11. Nigel Walker, Managing Director, That's Nice
    Specialist field: Markets
  12. Roger Bakale, Vice President CMC and Clinical Supply Chain, Receptos
    Specialist field: Drug Discovery, Chemical Processes, R&D

The board will help CPhI to identify industry hot topics, as well as contribute its expertise to CPhI editorial. A key goal is to ensure that the CPhI content platforms address the industry's concerns and challenges, whilst creating forums for industry professionals to exchange ideas, discover new opportunities and find solutions to their most critical problems.

The board will meet annually and take part in regular conference calls in order to provide strategic insights into current plans and future development priorities, along with key practical issues surrounding the pharma industry and CPhI.